Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Integrin alpha L/CD11a Alexa Fluor 405-conjugated Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems FAB35951V100UG
This item is not returnable.
View return policy
Description
Integrin alpha L/CD11a Monoclonal specifically detects Integrin alpha L/CD11a in Human samples. It is validated for Flow Cytometry.Specifications
Integrin alpha L/CD11a | |
Monoclonal | |
0.2 mg/mL | |
Flow Cytometry 0.25-1 ug/10^6 cells | |
CD11 antigen-like family member A, CD11a, CD11a antigen, CD11Aantigen CD11A (p180), lymphocyte function-associated antigen 1, alphapolypeptide, integrin alpha-L, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen1; alpha polypeptide), ITGAL, Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1, LFA-1 alpha, LFA1A, LFA-1A, Ly-15, Ly-21, lymphocyte function-associated antigen 1 | |
Mouse | |
100 μg | |
Primary | |
Detects human Integrin alpha L/CD11a in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) Integrin alpha 1, alpha 2, alpha 3, alpha 4, alpha 5, alpha 6, alpha 8, alpha 9, alpha 10, alpha 11, alpha M, alpha V, alpha X, rhIntegrin beta 3, rhIntegrin alpha 6(x1)+ beta 4, alpha 7(x2)+ beta 1, alpha D+ beta 2, alpha E+ beta 7, recombinant mouse Integrin alpha 2b or alpha L is observed. | |
Store the unopened product at 2 - 8 degreesC. Do not use past expiration date. |
Flow Cytometry | |
CR38 | |
Alexa Fluor 405 | |
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. with 0.09% Sodium Azide | |
ITGAL | |
Fibronectin purified human monocytes | |
RUO | |
3683 | |
Human | |
IgG2a |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only (RUO)
Spot an opportunity for improvement?Share a Content Correction